• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Gastroenterology

Quick Take: Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials

byDonna LeetandAliya Ramjaun
February 9, 2019
in Gastroenterology, Infectious Disease
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

RELATED REPORTS

Oral microbiome therapy reduced Clostridioides difficile recurrence

Very-low-calorie diet leads to significant but reversible changes in gut microbiome

Wellness Check: Nutrition

Several recently published guidelines regarding the treatment of C. difficile infection recommend vancomycin as first-line antibiotic treatment. However, given the recent increase in severity and frequency of C. difficile infections, there is a critical need for novel C. difficile therapies. Cadazolid is a novel quinoxolidinone antibiotic that acts in the intestinal lumen by inhibiting bacterial protein synthesis, and was shown to have similar efficacy to vancomycin in the treatment of C. difficile in a phase 2 trial; a phase 3 trial has not yet been conducted. In two identically designed, phase 3, randomized, controlled non-inferiority studies (IMPACT 1 and IMPACT 2), a total of 1,263 patients with mild-to-moderate or severe C. difficile infection were assigned to receive cadazolid or vancomycin to study clinical cure, defined as the resolution of diarrhea for two days after the end of treatment with no additional treatment for C. difficile infection. In both trials, patients in the vancomycin group had a higher percentage of epidemic strains. Based on a modified intention-to-treat population, cadazolid was found to be noninferior to vancomycin in the incidence of clinical cure in IMPACT 1 (84% in the cadazolid group vs. 85% in the vancomycin group, treatment difference -1.4, 95% CI -7.2 to 4.3). However, cadazolid was not noninferior to vancomycin in the incidence of clinical cure in IMPACT 2 (81% in the cadazolid group vs. 86% in the vancomycin group, treatment difference -4.7, 95% CI -10.7 to 1.3). In both studies, cadazolid had a similar safety profile to vancomycin. Overall, non-inferiority of cadazolid compared with vancomycin for C. difficile infection was only shown in one of two studies. Further investigation of cadazolid for the treatment of C. difficile infections will likely not be pursued.

Click to read the study in Lancet Infectious Diseases

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: CadazolidClostridium difficileVancomycin
Previous Post

Porphyria recurrence in a transplant recipient illustrates the need for genetic screening of related organ donors

Next Post

Primary care utilization associated with increased high-value care

RelatedReports

[Physician Comment] The extent of C. difficile infections may not differ in light of immune status
Gastroenterology

Oral microbiome therapy reduced Clostridioides difficile recurrence

January 24, 2022
Of Background Image
Gastroenterology

Very-low-calorie diet leads to significant but reversible changes in gut microbiome

July 27, 2021
Provision of medically-tailored meals linked with lower admissions and medical spending
Wellness

Wellness Check: Nutrition

July 22, 2021
#VisualAbstract: Afabicin is non-inferior to vancomycin and linezolid for staphylococcal skin and soft tissue infections
StudyGraphics

#VisualAbstract: Afabicin is non-inferior to vancomycin and linezolid for staphylococcal skin and soft tissue infections

August 19, 2020
Next Post

Primary care utilization associated with increased high-value care

Adjunctive TMP-SMX (Bactrim) associated with higher clinical cure rates for cutaneous abscesses

Quick Take: Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial

Quick Take: Impact of scribes on emergency medicine doctors’ productivity and patient throughput: multicentre randomised trial

Quick Take: Impact of scribes on emergency medicine doctors’ productivity and patient throughput: multicentre randomised trial

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Gratitude-focused writing may improve mental wellness during periods of chronic stress
  • Adebrelimab plus chemotherapy improves overall survival in extensive-stage small-cell lung cancer
  • Tiragolumab with atezolizumab is a promising treatment option for PD-L1 positive advanced non-small-cell-lung cancer
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.